Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
HumanaMedicare Advantage · Prior Auth · Medicare Advantage · Rheumatology, Oncology, PediatricsHigh impact

Intravenous tocilizumab products (Revised)

Act
immediately
Effective date
Jan 1, 2019
Identified
Jun 25, 2026

Summary

Humana Medicare Advantage has revised its prior authorization policy for intravenous tocilizumab products (Actemra, Tyenne, Tofidence, Avtozma) effective January 1, 2019, with the most recent revision dated October 22, 2025. The policy establishes specific clinical criteria and exclusions for coverage across five indications: rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, cytokine release syndrome, and giant cell arteritis. Billing teams must implement prior authorization requirements and enforce step therapy protocols requiring documented prior therapy or contraindications with specific biologics before tocilizumab approval.

Get alerts when payers change rules like this one

We check Humana and other payers every day and email you when a change matches your specialty and state.

Get Humana alertsPolicy Monitoring is free. No card required.

What to do

immediately · 7 steps
01Billing and clinical teams must implement prior authorization procedures for all intravenous tocilizumab products (Actemra, Tyenne, Tofidence, Avtozma) under this Humana Medicare Advantage policy.
02Update billing system to require prior auth for HCPCS codes J9310, J9311, and J9312.
03For rheumatoid arthritis and cytokine release syndrome cases, enforce step therapy documentation requirement: verify member has failed, contraindication, or intolerance to Remicade, Inflectra, Infliximab, or Simponi Aria before authorization (exception: renewal within 365 days).
04For all indications, billing team must verify age requirements are met (18+ years for rheumatoid arthritis and giant cell arteritis; 2+ years for juvenile arthritis and CRS) and confirm no concurrent biologic therapy is present (Cosentyx, Enbrel, adalimumab products, Kevzara, Remicade).
05Add prior auth denial rules to system: automatic rejection if combination biologic therapy identified or experimental indication.
06Claims submitted without prior authorization or failing to meet clinical criteria will be denied.
07Before January 15, 2026, audit recent tocilizumab claims for compliance with new revision requirements and resubmit any that lacked proper prior auth documentation.

Codes mentioned

J9310J9311J9312

Original notice

Intravenous tocilizumab products (Revised)
mcp.humana.com · Always check the source before changing claims.
View original ↗

Related changes

See all Humana changes →
Rituximab products (Revised)MediumEffective Jan 1, 2026 · MedicaidRituximab Products (Revised)HighEffective Jan 1, 2023 · Medicare AdvantageRituximab Products (New)HighEffective Oct 28, 2026 · MedicaidZynyz (retifanlimab-dlwr) (New)MediumEffective Oct 1, 2025 · MedicaidBrowse every Humana change in the policy list

Related policy hubs

Humana policiesRheumatologyOncologyPediatricsCode J9310Code J9311Code J9312

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account